Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug

James Q. Del Rosso; Leon H. Kircik; Linda Stein Gold; Hilary Baldwin; Jonathan S. Weiss; David M. Pariser; Valerie Callender; Edward Lain; Michael Gold; Kenneth Beer; Zoe D. Draelos; Neil Sadick; Radhakrishnan Pillai; Varsha Bhatt; Emil A. Tanghetti

doi:10.25251/skin.6.supp.17

Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug

James Q. Del Rosso, Leon H. Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan S. Weiss, David M. Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe D. Draelos, Neil Sadick, Radhakrishnan Pillai, Varsha Bhatt, Emil A. Tanghetti

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	s17
Journal	SKIN: Journal of Cutaneous Medicine
Volume	6
Issue number	2
DOIs	https://doi.org/10.25251/skin.6.supp.17
State	Published - 4 Mar 2022

Access to Document

10.25251/skin.6.supp.17

Cite this

Del Rosso, J. Q., Kircik, L. H., Gold, L. S., Baldwin, H., Weiss, J. S., Pariser, D. M., Callender, V., Lain, E., Gold, M., Beer, K., Draelos, Z. D., Sadick, N., Pillai, R., Bhatt, V., & Tanghetti, E. A. (2022). Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug. SKIN: Journal of Cutaneous Medicine, 6(2), s17. https://doi.org/10.25251/skin.6.supp.17

@article{2ef1df81d14440dc90c4c947ed22594c,

title = "Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug",

author = "{Del Rosso}, {James Q.} and Kircik, {Leon H.} and Gold, {Linda Stein} and Hilary Baldwin and Weiss, {Jonathan S.} and Pariser, {David M.} and Valerie Callender and Edward Lain and Michael Gold and Kenneth Beer and Draelos, {Zoe D.} and Neil Sadick and Radhakrishnan Pillai and Varsha Bhatt and Tanghetti, {Emil A.}",

note = "Funding Information: ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC Funding Information: JQDR has served as a consultant, investigator, and/or speaker for Ortho Dermatologics, Abbvie, Amgen, Arcutis, Dermavant, EPI Heath, Galderma, Incyte, LEO Pharma, Lilly, MC2 Therapeutics, Pfizer, Sun Pharma, and UCB LHK has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. LSG has served as investigator/consultant or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharma, UCB, Arcutis and Lilly. HB has served as advisor, investigator, and on speakers{\textquoteright} bureaus for Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma. JSW is a consultant, speaker, advisor, and/or researcher for AbbVie, Ortho Dermatologics, Janssen Biotech, Dermira, Almirall, Brickell Biotech, DermTech, Scynexis. DMP has served as consultant to Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Celgene, Dermira, LEO Pharma, Regeneron, Sanofi, TDM SurgiTech, TheraVida, and Ortho Dermatologics; investigator for Abbott Laboratories, Almirall, Amgen, AOBiome, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant, Dermira, Eli Lilly, LEO Pharma, Menlo Therapeutics, Merck & Co., Novartis, Novo Nordisk A/S, Ortho Dermatologics, Pfizer, Regeneron, and Stiefel; on advisory board for Pfizer; and on the data monitoring board for BMS. VC has served as an investigator, consultant, or speaker for AbbVie, Galderma, L{\textquoteright}Or{\'e}al, Ortho Dermatologics, and Vyne. EL has nothing to disclose. MG has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. KB has received funding from Allergan, Galderma, Evolus, and Revance. ZDD received research funding from Ortho Dermatologics. NS has served on advisory boards, as a consultant, investigator, speaker, and/or other and has received honoraria and/or grants/research funding from Almirall, Actavis, Allergan, Anacor Pharmaceuticals, Auxilium Pharmaceuticals, Bausch Health, Bayer, Biorasi, BTG, Carma Laboratories, Cassiopea, Celgene Corporation, Cutera, Cynosure, DUSA Pharmaceuticals, Eclipse Medical, Eli Lilly and Company, Endo International, EndyMed Medical, Ferndale Laboratories, Galderma, Gerson Lehrman Group, Hydropeptide, Merz Aesthetics, Neostrata, Novartis, Nutraceutical Wellness, Palomar Medical Technologies, Prescriber{\textquoteright}s Choice, Regeneron, Roche Laboratories, Samumed, Solta Medical, Storz Medical AG, Suneva Medical, Vanda Pharmaceuticals, and Venus Concept. VB and RP are employees of Bausch Health US, LLC and may hold stock and/or stock options in its parent company. EAT has served as speaker for Novartis, Ortho Dermatologics, Sun Pharma, Lilly, Galderma, AbbVie, and Dermira; served as a consultant/clinical studies for Hologic, Ortho Dermatologics, and Galderma; and is a stockholder for Accure..",

year = "2022",

month = mar,

day = "4",

doi = "10.25251/skin.6.supp.17",

language = "English",

volume = "6",

pages = "s17",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "2",

}

Del Rosso, JQ, Kircik, LH, Gold, LS, Baldwin, H, Weiss, JS, Pariser, DM, Callender, V, Lain, E, Gold, M, Beer, K, Draelos, ZD, Sadick, N, Pillai, R, Bhatt, V & Tanghetti, EA 2022, 'Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug', SKIN: Journal of Cutaneous Medicine, vol. 6, no. 2, pp. s17. https://doi.org/10.25251/skin.6.supp.17

TY - JOUR

T1 - Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne

T2 - Phase 2 Study of the First Triple-Combination Drug

AU - Del Rosso, James Q.

AU - Kircik, Leon H.

AU - Gold, Linda Stein

AU - Baldwin, Hilary

AU - Weiss, Jonathan S.

AU - Pariser, David M.

AU - Callender, Valerie

AU - Lain, Edward

AU - Gold, Michael

AU - Beer, Kenneth

AU - Draelos, Zoe D.

AU - Sadick, Neil

AU - Pillai, Radhakrishnan

AU - Bhatt, Varsha

AU - Tanghetti, Emil A.

N1 - Funding Information: ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC Funding Information: JQDR has served as a consultant, investigator, and/or speaker for Ortho Dermatologics, Abbvie, Amgen, Arcutis, Dermavant, EPI Heath, Galderma, Incyte, LEO Pharma, Lilly, MC2 Therapeutics, Pfizer, Sun Pharma, and UCB LHK has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. LSG has served as investigator/consultant or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharma, UCB, Arcutis and Lilly. HB has served as advisor, investigator, and on speakers’ bureaus for Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma. JSW is a consultant, speaker, advisor, and/or researcher for AbbVie, Ortho Dermatologics, Janssen Biotech, Dermira, Almirall, Brickell Biotech, DermTech, Scynexis. DMP has served as consultant to Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Celgene, Dermira, LEO Pharma, Regeneron, Sanofi, TDM SurgiTech, TheraVida, and Ortho Dermatologics; investigator for Abbott Laboratories, Almirall, Amgen, AOBiome, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant, Dermira, Eli Lilly, LEO Pharma, Menlo Therapeutics, Merck & Co., Novartis, Novo Nordisk A/S, Ortho Dermatologics, Pfizer, Regeneron, and Stiefel; on advisory board for Pfizer; and on the data monitoring board for BMS. VC has served as an investigator, consultant, or speaker for AbbVie, Galderma, L’Oréal, Ortho Dermatologics, and Vyne. EL has nothing to disclose. MG has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. KB has received funding from Allergan, Galderma, Evolus, and Revance. ZDD received research funding from Ortho Dermatologics. NS has served on advisory boards, as a consultant, investigator, speaker, and/or other and has received honoraria and/or grants/research funding from Almirall, Actavis, Allergan, Anacor Pharmaceuticals, Auxilium Pharmaceuticals, Bausch Health, Bayer, Biorasi, BTG, Carma Laboratories, Cassiopea, Celgene Corporation, Cutera, Cynosure, DUSA Pharmaceuticals, Eclipse Medical, Eli Lilly and Company, Endo International, EndyMed Medical, Ferndale Laboratories, Galderma, Gerson Lehrman Group, Hydropeptide, Merz Aesthetics, Neostrata, Novartis, Nutraceutical Wellness, Palomar Medical Technologies, Prescriber’s Choice, Regeneron, Roche Laboratories, Samumed, Solta Medical, Storz Medical AG, Suneva Medical, Vanda Pharmaceuticals, and Venus Concept. VB and RP are employees of Bausch Health US, LLC and may hold stock and/or stock options in its parent company. EAT has served as speaker for Novartis, Ortho Dermatologics, Sun Pharma, Lilly, Galderma, AbbVie, and Dermira; served as a consultant/clinical studies for Hologic, Ortho Dermatologics, and Galderma; and is a stockholder for Accure..

PY - 2022/3/4

Y1 - 2022/3/4

UR - http://www.scopus.com/inward/record.url?scp=85136302041&partnerID=8YFLogxK

U2 - 10.25251/skin.6.supp.17

DO - 10.25251/skin.6.supp.17

M3 - Comment/debate

AN - SCOPUS:85136302041

SN - 2574-1624

VL - 6

SP - s17

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -